Search

everythinglearnresearchcommunity

for

Search:↓

5-alpha-reductase inhibitors can effectively treat benign prostatic hyperplasia.

Targeting the PGI2 pathway may help heal diabetic foot ulcers.

Compound 4 is a promising treatment for hair loss with low toxicity.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.

Both drugs lower DHT levels, with GI198745 being more effective.

New dissolving and implantable microneedle patches have been created for a long-lasting, non-invasive delivery of the drug finasteride.

Finasteride effectively blocks rat enzymes, but with varying methods and strength.

20(S)-Protopanaxadiol-aglycone may help prevent and treat prostate cancer by reducing androgen receptor activity.

New compounds called benzoquinolinones may treat conditions linked to excess DHT.

Lysocellin helps stop cell damage from etoposide and may prevent hair loss.

Combination therapy improves urinary flow and reduces residual urine, but needs better stent design.

A reliable method was developed to measure Finasteride and Tadalafil together, showing they degrade under certain conditions.

New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.

Nifedipine may help treat perniosis, improving symptoms and clearing lesions for some patients.

The new fluoroquinolone effectively fights certain bacteria.

The document concludes that research on sulfatase inhibitors should continue due to their potential in treating various diseases, despite some clinical trial failures.

PNU157706 reduced rat sperm movement and fertility without affecting offspring health.

The document concludes that Catalyst software is effective for drug design, identifying potent compounds for various medical conditions.

PPCM microspheres can effectively release finasteride over 42 days.

Finasteride may cause changes in dopamine-related genes, possibly leading to post-finasteride syndrome.

New progesterone-based compounds can block male hormones.

Dutasteride may help protect neurons and reduce inflammation in Parkinson's disease.

New compounds were made that effectively block enzymes related to prostate issues and hair loss.

Finasteride may affect PNMT, causing side effects.

LGF injections may improve early Peyronie's disease by reducing penile curvature and plaque size.